Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cefixime multiple-dose pharmacokinetic and safety study in healthy pregnant women
ACTRN12625001175460Phase 3Not yet recruiting
- Sponsor
- World Health Organization
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of cefixime in syphilis and congenital syphilis (CS), sponsored by World Health Organization. Primary endpoints: Pharmacokinetic disposition after multiple doses of cefixime and Adverse events and treatment tolerability. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
cefixime
03
Conditions
syphiliscongenital syphilis (CS)
Beyond the preview
Go deeper on ACTRN12625001175460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625001175460.